[Federal Register: August 29, 2006 (Volume 71, Number 167)]
[Page 51197]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Allergenic Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Allergenic Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 13, 2006 from 
12 noon to approximately 3:45 p.m.
    Location: National Institutes of Health, Bldg. 29B, Conference 
Rooms A and B, Bethesda, MD.
    Contact Person: Gail Dapolito or Jane Brown, Center for Biologics 
Evaluation and Research (HFM-71), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852, 301-827-0314 or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 3014512388. Please call the Information Line 
for up-to-date information on this meeting.
    Agenda: On September 13, 2006, the committee will discuss a 
proposed strategy for the reclassification of Category IIIA allergenic 
products. The committee will also receive an update of the research 
program of the Laboratory of Immunobiochemistry, Division of Bacterial, 
Parasitic and Allergenic Products, Center for Biologics Evaluation and 
    Procedure: On September 13, 2006, from 12 noon to approximately 
3:15 pm, the meeting is open to the public. Interested persons may 
present data, information, or views, orally or in writing, on issues 
pending before the committee. Written submissions may be made to the 
contact person on or before September 6, 2006. Oral presentations from 
the public will be scheduled between approximately 1:45 pm and 2:45 pm. 
Time allotted for each presentation may be limited. Those desiring to 
make formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before September 6, 2006.
    Closed Committee Deliberations: On September 13, 2006 from 
approximately 3:15 pm to 3:45 p.m., the meeting will be closed to 
permit discussion where disclosure would constitute a clearly 
unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The 
committee will discuss individual research programs in the Office of 
Vaccines Research and Review.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Gail Dapolito at 
least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 23, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-14295 Filed 8-28-06; 8:45 am]